Akari Therapeutics Plc ADR (AKTX)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA Summary
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Increases By 151.7%
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) saw a significant growth in short interest in April. As of April 15th, there was short interest totaling 14,622 shares, a growth of 151.7% from the March 31st total of 5,810 shares. Based on an average trading volume of 45,393 shares, the days-to-cover ratio is presently 0.3
Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript
Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript
Akari Therapeutics, Plc (AKTX) Shareholder/Analyst Call Transcript
Akari Therapeutics, Plc ( AKTX ) Shareholder/Analyst Call November 18, 2025 11:00 AM EST Company Participants Abizer Gaslightwala - CEO, President & Director Satyajit Mitra - Executive Director & Head of Oncology Conference Call Participants Jenene Thomas Presentation Jenene Thomas Okay. We are ready to get started, and welcome, everyone, to the Akari Therapeutics Corporate Update Webcast.
Akari Therapeutics Plc ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 38,922 | $200,448 | $305,926.92 | $105,478.92 | 52.62% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 8 | $77.52 | $62.88 | -$14.64 | -18.89% |
Akari Therapeutics Plc ADR (AKTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Akari Therapeutics Plc ADR ever had a stock split?
Akari Therapeutics Plc ADR Profile
| Biotechnology Industry | Healthcare Sector | Abizer Gaslightwala CEO | NASDAQ (CM) Exchange | 00972G405 CUSIP |
| US Country | 6 Employees | - Last Dividend | 31 Mar 2026 Last Split | 21 Sep 2015 IPO Date |
Overview
Akari Therapeutics, Plc is a forward-thinking clinical-stage biopharmaceutical company primarily engaged in the discovery and development of innovative treatments for a range of autoimmune and inflammatory diseases. With its foundations deeply rooted in cutting-edge scientific research, Akari is dedicated to addressing some of the most challenging medical conditions with limited treatment options available. Positioning itself as a leader in the field, the company's strategic focus on complement inhibitors showcases its commitment to pioneering approaches that have the potential to transform the lives of patients worldwide. Based in the bustling city of London in the United Kingdom, Akari Therapeutics leverages its geographical location to foster collaborations and access a wide network of research and development opportunities to advance its mission.
Products and Services
- Nomacopan - Akari’s flagship product candidate, nomacopan, stands as a beacon of hope for patients suffering from a variety of severe autoimmune and inflammatory diseases. This second-generation complement inhibitor is designed to halt the inflammatory and prothrombotic activities that are characteristic of disorders such as paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. By targeting the underlying mechanisms that drive these conditions, nomacopan could significantly improve the quality of life for those affected.
- PASylated-Nomacopan - In its relentless pursuit of innovation, Akari is also advancing a pre-clinical program focused on the development of a long-acting version of nomacopan. This PASylated-nomacopan variant is engineered to extend the molecule's half-life, thereby offering a potentially transformative treatment option for geographic atrophy secondary to dry age-related macular degeneration. This advancement underscores Akari’s dedication to pushing the boundaries of science to uncover new solutions for diseases with substantial unmet needs.
